[Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis].
To improve bone mass and quality two strategies are currently taken ; one is the indirect stimulation of bone formation through the endogenous parathyroid function augmented by anti-resorptive agents that do not have a direct suppressive effect on the osteoblastic function, and the other is the direct osteoblast stimulation by agents themselves. The former group includes anti-RANKL antibody and cathepsin K inhibitors and the latter has strontium ranelate, teriparatide, and anti-sclerostin antibody. Clinical data of these drugs in osteoporosis are expected.